A
A. Liberati
Researcher at Mario Negri Institute for Pharmacological Research
Publications - 17
Citations - 5347
A. Liberati is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Breast cancer & Health care. The author has an hindex of 12, co-authored 17 publications receiving 5335 citations.
Papers
More filters
Journal Article
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher,A. Liberati,Jennifer Tetzlaff,Douglas G. Altman,Gerd Antes,David C. Atkins,Virginia Barbour,Nick Barrowman,Jesse A. Berlin,Jocalyn Clark,Mike Clarke,Deborah J. Cook,Roberto D'Amico,Jonathan J Deeks,Philip J. Devereaux,Kay Dickersin,Matthias Egger,E Ernst,Peter C. Gøtzsche,Jeremy M. Grimshaw,G. H. Guyatt,Julian P T Higgins,Ioannidis Jpa.,Jos Kleijnen,Tom Lang,Nicola Magrini,D McNamee,Lorenzo Moja,Cynthia D. Mulrow,Maryann Napoli,Andrew D Oxman,B Pham,Drummond Rennie,Margaret Sampson,Kenneth F. Schulz,Paul G. Shekelle,David Tovey,Peter Tugwell +37 more
TL;DR: The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) as discussed by the authors is an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses.
Journal ArticleDOI
Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
TL;DR: This systematic review of RCTs on HCC indicates that the non-surgical current treatments are ineffective or minimally and uncertainly effective and can deserve further assessment by larger and methodologically more sound randomized trials.
Journal ArticleDOI
Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients
TL;DR: Care provided by specialized centres/clinicians appeared to be better both when assessed in relation to process indicators and to mortality, but this evidence should be considered far from conclusive because of major methodological flaws in these studies.
Journal ArticleDOI
A Meta‐analysis of Trials on Aldose Reductase Inhibitors in Diabetic Peripheral Neuropathy
Antonio Nicolucci,Fabrizio Carinci,D. Cavaliere,N. Scorpiglione,Maurizio Belfiglio,D Labbrozzi,E. Mari,M. Massi Benedetti,Gianni Tognoni,A. Liberati +9 more
TL;DR: Although the results of 1‐year treatment on motor NCV seem encouraging, the uncertainty about the reliability of the end‐point employed and the short treatment duration do not allow any clear conclusion about the efficacy of ARIs in the treatment of peripheral diabetic neuropathy.
Journal ArticleDOI
EUR-ASSESS Project Subgroup Report on Methodology: Methodological Guidance for the Conduct of Health Technology Assessment
TL;DR: The quality of decisions can be improved by a process that provides a consistent framework for identifying and assessing health technologies.